Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 10.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company’s stock after selling 219,400 shares during the quarter. Amova Asset Management Americas Inc. owned 1.64% of Intellia Therapeutics worth $25,275,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of NTLA. ARK Investment Management LLC grew its stake in Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after purchasing an additional 1,965,181 shares during the last quarter. State Street Corp grew its position in shares of Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after purchasing an additional 1,447,967 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after purchasing an additional 107,333 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Intellia Therapeutics by 7.6% during the 3rd quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock worth $42,305,000 after purchasing an additional 173,033 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades A number of research firms recently issued reports on NTLA. The Goldman Sachs Group upped their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research note on Tuesday, April 28th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 15th. Wedbush boosted their price target on Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective on the stock. in a research report on Wednesday, July 15th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.19.
View Our Latest Research Report on NTLA
Insider Transactions at Intellia Therapeutics In other news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 3.50% of the company’s stock.
Intellia Therapeutics Stock Down 4.0% Shares of NASDAQ:NTLA opened at $10.92 on Tuesday. The company has a market cap of $1.53 billion, a P/E ratio of -3.08 and a beta of 1.77. Intellia Therapeutics, Inc. has a 52 week low of $7.95 and a 52 week high of $28.25. The business has a fifty day simple moving average of $14.22 and a 200-day simple moving average of $13.44.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. During the same period in the prior year, the firm posted ($1.10) earnings per share. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.
Intellia Therapeutics Profile (Free Report)
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Recommended Stories Five stocks we like better than Intellia Therapeutics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFigma, Inc. $FIG Stock Position Raised by Amova Asset Management Americas Inc.
NEXT HEADLINE »Cameco Corporation $CCJ Shares Acquired by Amova Asset Management Americas Inc.
Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmaceutical and biotechnology companies seeking deeper insight into disease biology and more effective therapeutic strategies.
It is important to distinguish between genetics and genomics. While genetics focuses on individual genes, genomics primarily aims to characterize all the genes of an organism. Genomics helps understand how genes operate within a living system and how they interact with one another and their environment.
Insights from genomic research are increasingly being used to evaluate how patients respond to specific drugs. These findings are also driving the development of precise, more targeted treatments, contributing to the advancement of personalized medicine. As demand for innovative therapies continues to grow, genomics is poised to play an increasingly central role in the future of healthcare, despite the complexity inherent in genome-scale research.
The expanding genomics landscape has also supported the growth of synthetic biology, which applies engineering principles to biology. This emerging field involves redesigning organisms for diverse applications, including drug discovery, disease detection, enzyme engineering, gene editing and foundational research.
The rapid progress in the novel space of genomics has been fueled by steep declines in the cost, time, and effort needed to sequence an individual’s genome. A major player in this field is Illumina (ILMN - Free Report) , a global leader in sequencing and array-based solutions for genetic and genomic analysis.
Diagnostic companies are using genomic sequencing data to identify genetic variations and connect them to known diseases. In contrast, other companies apply sequencing technologies to develop solutions across healthcare and other industries.
Another major advancement in the field is the emergence of genome-editing technologies, most notably CRISPR/Cas9. Companies specializing in gene editing, such as CRISPR Therapeutics AG (CRSP - Free Report) and Intellia Therapeutics, Inc. (NTLA - Free Report) , are exploring these tools to potentially treat or even cure diseases caused by genetic mutations. As the name implies, these technologies enable precise modifications to an organism’s DNA, allowing scientists to correct harmful defects at their source.
According to Fortune Business Insights, the global genomics market was valued at $34.23 billion in 2025 and is expected to expand from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% over the period.
Per a Grandview Research article, the global synthetic biology market size was valued at $18.9 billion in 2025 and is projected to reach $69.2 billion by 2033, at a CAGR of 17.7% from 2026 to 2033.
If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, stocks such as Myriad Genetics (MYGN - Free Report) , Sana Biotechnology (SANA - Free Report) and Wave Life Sciences (WVE - Free Report) hold potential.
Explore 39 cutting-edge investment themes with Zacks Thematic Investing Screens and uncover your next big opportunity.
3 Genomics Stocks to ConsiderMyriad Genetics is a molecular diagnostics and precision medicine company focused on improving patient outcomes through advanced genetic testing. The company develops and commercializes innovative molecular diagnostic solutions that provide genetic insights to patients and healthcare providers. Its tests help evaluate disease risk, predict disease progression, and inform treatment decisions across multiple medical specialties. By enabling earlier detection, more personalized therapies, and better-informed clinical care, Myriad aims to enhance patient outcomes while helping reduce overall healthcare costs.
The company is experiencing strong momentum across its core cancer diagnostics business. Per management, its Cancer Care Continuum strategy is gaining traction, supported by a dedicated hereditary cancer sales force and targeted initiatives aimed at driving continued growth in germline testing. Management’s initiatives to strengthen the Prenatal Health business are expected to support stronger performance over the remainder of 2026. The limited launch of its Precise MRD test for breast cancer has generated encouraging early feedback. The company remains on track to launch additional tests in 2026, which it expects to become key growth drivers beginning in 2027.
Myriad Genetics also carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sana Biotechnology is developing ex vivo and in vivo cell engineering platforms to revolutionize treatment of various diseases, such as type 1 diabetes (T1D), B-cell cancers and B-cell mediated autoimmune diseases. The company is advancing three lead therapeutic candidates built on its proprietary platform technologies. These include SC451, a HIP-edited product candidate for the treatment of type 1 diabetes for type 1 diabetes; SG293, an in vivo CAR T therapy for B-cell malignancies and B-cell-mediated autoimmune diseases; and SG227, an in vivo CAR T therapy for multiple myeloma. The company retains worldwide commercial rights to all three programs.
The company has collaborated with Mayo Clinic to advance development of SC451. Sana expects to file an investigational new drug application and begin a phase I study for SC451 as this year. Sana also plans to initially evaluate SG293 in non-Hodgkin lymphoma and report first-in-human data as early as this year. If successful, the company intends to expand SG293 into B-cell-mediated autoimmune diseases and advance SG227 into clinical studies for multiple myeloma.
SANA currently carries a Zacks Rank #2.
Wave Life Sciences is a clinical-stage biotechnology company harnessing the broad potential of ribonucleic acid (RNA) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. The company’s proprietary RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights with human genetics to deliver scientific breakthroughs that treat both rare and common disorders.
Its proprietary PRISM platform integrates multiple RNA-targeting approaches, including RNA interference (SpiNA) and RNA editing (AIMers), to create precision therapies. It boasts a diverse pipeline, including programs for obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), PNPLA3 I148M-associated liver disease (WVE-008), Duchenne muscular dystrophy, Huntington's disease, and several preclinical candidates.
The company initiated the phase IIa multidose portion of the INLIGHT study, a placebo-controlled (3:1) study evaluating WVE-007 as monotherapy in individuals living with obesity with high BMI (35-50 kg/m2) and comorbidities. The company remains on track to launch additional phase II studies in the second half of 2026 evaluating WVE-007, both in combination with incretin therapies and as a maintenance treatment following incretin use.
July 06, 2026 16:05 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
Intellia Therapeutics (NTLA +1.89%) has been on fire this year. Shares of the clinical-stage biotech have climbed an impressive 83% to date. However, Wall Street remains bullish on the company. Intellia Therapeutics' average price target (according to Yahoo! Finance) is $26.63, implying the stock could jump another 57% from its current levels over the next year. Should investors rush to purchase Intellia Therapeutics' shares based on The Street's bullish sentiments?
Image source: Getty Images.
Why there could be more upside ahead Intellia Therapeutics has performed well largely thanks to strong clinical progress with its leading candidate, lonvo-z, an investigational gene editing medicine for hereditary angioedema (HAE), a rare condition that causes painful and dangerous swelling attacks across the body. Though there are standards of care for this disease that help manage swelling attacks, there is no cure. Intellia Therapeutics hopes it has developed the closest thing to a cure with lonvo-z. In a phase 3 clinical trial, patients treated with a single infusion of lonvo-z experienced an 87% reduction in attacks after a six-month evaluation period compared with those who received a placebo. Further, 62% of patients were completely attack-free, compared with just 11% in the placebo group.
Lonvo-z now looks destined for approval, and Intellia Therapeutics has already begun submitting an application package to the U.S. Food and Drug Administration (FDA). What's more, Intellia Therapeutics could have another important catalyst over the next 12 to 18 months. The company is developing another gene-editing treatment, nex-z, in collaboration with Regeneron (REGN +0.19%). Nex-z is undergoing a pair of phase 3 studies in patients with a rare, progressive genetic disease called transthyretin (ATTR) amyloidosis, which can cause severe cardiovascular problems. The company may release data from these clinical trials sometime next year. Provided the results are positive, Intellia's shares may soar.
Today's Change
(
1.89
%) $
0.32
Current Price
$
17.24
Significant risks involved The commercial opportunity across lonvo-z and nex-z looks attractive, largely because of the latter. Only one person in 50,000 is affected by HAE, so there could be around 7,000 patients with the disease in the U.S., and about 162,000 worldwide. Of course, lonvo-z won't capture this entire opportunity, even under an optimistic scenario. It may not earn approval outside the U.S., for instance. So, lifetime sales for lonvo-z may not be that impressive. And annual revenue from the therapy will be even lower.
But once we turn to nex-z, the landscape looks different. The hereditary version of ATTR amyloidosis affects 50,000 people worldwide, while the wild type (that comes with age) affects between 200,000 and 500,000 patients. Diagnosis rates are also increasing, particularly for wild-type ATTR amyloidosis, driven by the world's aging population. And thanks to its partnership with the larger, more experienced Regeneron, Intellia Therapeutics could launch this medicine in many markets worldwide.
So, nex-z is central to Intellia Therapeutics' prospects. However, investors should keep in mind that the stock is very risky. Any clinical-stage biotech company tends to be so. True, Intellia's phase 3 success with lonvo-z makes its outlook less uncertain, but a lot could still happen, including unforeseen regulatory setbacks that aren't that uncommon with smaller drugmakers. Further, it's also worth noting that the company has had some issues with nex-z. Last year, the FDA placed clinical trials for the medicine on hold after a patient who received it died due to liver damage.
While the FDA eventually lifted the clinical hold, more safety concerns may eventually arise and, perhaps, disrupt nex-z's progress. Then there is the fact that Intellia Therapeutics develops gene-editing treatments that tend to be very expensive, making it hard to get health insurance companies on board, even when they are effective. This could eventually pose a problem once (if) Intellia Therapeutics launches its medicines.
Is Intellia stock a buy? Intellia Therapeutics' recent phase 3 clinical trial success, its other late-stage candidate, and its strong cash balance all make a good case for the stock. The biotech ended the first quarter with $517.2 million in cash and equivalents, but it also conducted a secondary common stock offering after the period ended, raising about $207 million in gross proceeds. Management thinks the company has enough cash to last until 2028, even without factoring in the money it will receive from lonvo-z, once it hits the market.
However, some of Intellia Therapeutics' success with lonvo-z may already be baked into the stock price, and its shares won't move much once it's approved -- they could even decline if long-term shareholders decide to take that opportunity to pocket some profits. Further, the stock will fall off a cliff if it encounters any issue with nex-z. These factors make Intellia a risky bet. My view is that the stock is unlikely to match Wall Street's price target over the next 12 months.
And although it may have even more upside than that over the next five years if nex-z aces its phase 3 studies, the risks related to a potential failure on that front make the stock suitable only for those comfortable with significant volatility.
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
LCID stock is moving. See the chart and price action here. For short sellers, these are high‑conviction trades. For longs, they are potential powder kegs.
The image below shows the top 10 most heavily shorted stocks (market caps above $2 billion, average 14-day volume above 5 million and free floats above 5 million) based on data from Benzinga Pro as of June 29, 2026:
RH (NYSE:RH) follows closely, with short interest near 56.7% and a triple‑digit share price, giving bears significant exposure to any rebound in high‑end consumer spending or housing‑related demand.
The TakeawayWith short interest this elevated, the group is highly sensitive to any broad improvement in risk appetite or sector‑specific catalysts.
A stronger macro backdrop, easing rates or a string of positive company‑level headlines could flip the trade quickly, turning today’s crowded bearish trades into tomorrow’s forced‑buying stampedes.
For traders tracking potential squeeze setups, these 10 names are the current powder‑keg shortlist.
Photo: Militarist / Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Choosing between Intellia Therapeutics (NTLA +2.88%) and Omeros (OMER +1.53%) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan disease treatments.
Intellia Therapeutics focuses on permanent genetic cures using CRISPR technology, while Omeros develops protein and small-molecule therapies for rare diseases and cancers. While both operate in the high-risk, high-reward biotech stocks landscape, their financial profiles and clinical milestones offer different paths for retail investors.
Intellia Therapeutics is a clinical-stage leader focused on CRISPR-based gene editing to treat diseases at their genetic source. The company primarily advances therapies for hereditary angioedema (HAE) and transthyretin amyloidosis through its lead programs, lonvoguran ziclumeran and nexiguran ziclumeran. A core pillar of its strategy is a deep collaboration with Regeneron Pharmaceuticals (REGN +0.78%), which involves co-developing therapies for neurological and muscular diseases.
In FY 2025, revenue reached approximately $67.7 million, representing a year-over-year growth rate of nearly 17%. Despite this top-line growth, the company reported a net loss of roughly $412.7 million for the period. This isn;t unusual for a developmental stage biotech company.
As of its December 2025 balance sheet, the company maintains a very low debt-to-equity ratio of nearly 0.1x. This ratio measures total debt relative to shareholders’ equity, indicating a conservative approach to borrowing. Free cash flow was nearly negative $396 million.
The case for Omeros CorpOmeros is transitioning to a commercial-stage company following the FDA’s late 2025 approval of Yartemlea for the treatment of TA-TMA, transplant-associated thrombotic microangiopathy. Beyond its lead product, the company has secured a significant partnership with Novo Nordisk (NVO 0.48%) to develop zaltenibart, a MASP-3 inhibitor. This collaboration provides Omeros with potential milestone payments and royalties, which are essential for its long-term revenue strategy.
For FY 2025, Omeros had no revenue, as its first commercial product had only recently received regulatory approval. The company reported a net loss of approximately $3.4 million, a significant improvement over prior-year losses in the early stage of its commercial transition.
The company’s current balance sheet shows cash on hand of $135.3 million and debt of $226.6 million, a manageable level for an upstart biotech company.
Risk profile comparisonIntellia Therapeutics faces significant risks related to clinical development and regulatory hurdles. The Magnitude trial for nex-z remains on clinical hold following a patient death in late 2025, which could delay potential approvals. However, a similar trial, Magnititude-2, had its clinical hold lifted by the FDA in January. Additionally, the company is involved in complex intellectual property litigation with entities such as BlueAllele Corp. and the Broad Institute over CRISPR patent rights.
Omeros is heavily dependent on the successful market adoption of Yartemlea, its only commercial product. Any failure in physician or payer acceptance could materially harm its financial viability. Furthermore, the company relies on Novo Nordisk for the successful development of zaltenibart and carries significant debt, including convertible notes that are due in 2029.
Valuation comparisonIntellia Therapeutics is not forecast to have earnings so there is no forward price-to-earnings ratio, while Omeros carries a much higher premium to the sector following its recent product approval and smaller equity base.
MetricIntellia TherapeuticsOmerosSector BenchmarkForward P/EN/A58x24.6xP/S ratio28.5x74.2xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?Intellia Therapeutics’ CRISPR gene-editing technology for the treatment is showing promising Phase III trial data this spring, leading many to expect that the treatment for HAE could be approved by the FDA in the first half of 2027. If the promise of gene editing comes through, Intellia could have a run of significant treatments for diseases that have no treatment today. However, most of Intellia’s pipeline is very early stage. While the HAE treatment is in Phase III, the last stage before approval, it is worth noting that Phase III drugs are not guaranteed approval, and in some cases, even those that could receive approval are not brought to market because they are seen as unprofitable.
From a financial standpoint, Intella has financial resources for operations through 2028, so there is no urgent need to raise cash. But Wall Street sees the business continuing to post deep losses through 2029.
Omeros Corp is transitioning from a developmental-stage biotech to a commercial operation, so it looks like a safer bet. The company just posted its first-quarter revenue in 2026, reporting $9.89 million in sales of Yartemlea, a figure management says reflects strong interest in the treatment. The business posted huge net income, relative to sales, of $56.06 million, thanks to upfront payments from Novo Nordisk.
Since Yartemlea has just launched, management isn’t estimating sales and income for the current quarter. Sales teams are visiting every transplant facility in the U.S. this quarter to spread the word about the TM-TMA treatment. Wall Street is bullish, expecting about $68 million in revenue this year, then double that in 2027, with net income close to $22 million this year from licensing and a loss of $22 million next year.
Omneros comes at a premium to the sector, but it’s encouraging to see a biotech coming to market with firm initial sales, a very healthy balance sheet, and projections for relatively minor losses next year, followed by consistent profits.
Intellia could be a home run, but there’s a big risk of a swing and miss. Omeros gets the nod.
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Key Takeaways NTLA gained 23.2% after additional phase III HAELO results for lonvo-z in hereditary angioedema.NTLA reported an 89% reduction in attacks requiring on-demand treatment versus placebo.NTLA said lonvo-z cut moderate-to-severe attack rates by 91% compared with placebo. Shares of Intellia Therapeutics (NTLA - Free Report) were up 23.2% yesterday after the company reported additional positive data from the phase III HAELO study evaluating lonvo-z (formerly NTLA-2002), an in vivo CRISPR-based gene-editing therapy, for the treatment of hereditary angioedema (HAE).
What Did NTLA’s Additional Data Show?The latest data from the phase III HAELO study showed that treatment with lonvo-z reduced the monthly rate of attacks requiring on-demand by 89% and cut the monthly rate of moderate-to-severe attacks by 91% compared with placebo, the study’s other key secondary endpoints.
It can be inferred that the additional data further highlighted lonvo-z's potential to provide meaningful disease control for HAE patients. Investors appeared to be encouraged by the latest results, which likely contributed to the stock's gain following the announcement.
The data was presented at the European Academy of Allergy & Clinical Immunology annual conference 2026, held in Istanbul, Türkiye. It was also simultaneously published in the New England Journal of Medicine.
NTLA Price PerformanceYear to date, shares of Intellia have rallied 65.9% against the industry’s decline of 0.7%.
Image Source: Zacks Investment Research
NTLA’s Recent Development With Lonvo-ZIn April 2026, the company announced that the phase III HAELO study evaluating lonvo-z for the treatment of HAE had met its primary endpoint and a key secondary endpoint.
Data from the study showed that a one-time infusion of lonvo-z reduced HAE attacks by 87% compared with placebo over the six-month evaluation period, the primary endpoint of the study. The study also demonstrated that 62% of patients treated with lonvo-z were completely attack-free and therapy-free for six months, compared with just 11% with placebo, a key secondary endpoint of the HAELO study.
The treatment was well-tolerated, with mild-to-moderate side effects.
HAE is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin.
Also, in April, Intellia initiated a rolling submission of a biologics license application to the FDA seeking approval for lonvo-z for the treatment of HAE. The company plans to commercially launch lonvo-z in the first half of 2027, upon potential approval in the United States.
NTLA’s Zacks Rank & Stocks to ConsiderIntellia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Kiniksa Pharmaceuticals (KNSA - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Kiniksa Pharmaceuticals’ 2026 EPS have increased from $1.09 to $1.24. Over the same period, EPS estimates for 2027 have risen from $1.54 to $1.70. KNSA shares have increased 26.9% year to date.
Kiniksa Pharmaceuticals’ earnings beat estimates in two of the trailing four quarters and missed in the remaining two quarters, with the average surprise being 1.53%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 108.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
The Dow Jones Industrial Average (DJI) is up triple digits and fresh off another record high. Despite a rebound in the chip sector, the S&P 500 Index (SPX) sits flat and the Nasdaq Composite Index (IXIC) is trading modestly lower. Investors are eagerly awaiting the Federal Reserve's interest rate decision, due out at 2:00 p.m. ET, where rates are widely expected to remain unchanged. Meanwhile, oil prices are climbing after President Donald Trump said a peace deal with Iran had not yet been finalized, while SpaceX (SPCX) is finally cooling off from its post-IPO rally.
Continue reading for more on today's market, including:
Options traders eye CarMax stock amid post-earnings tumble. Software stock lands "buy" rating after 11-day losing streak. Plus, bulls target biotech stock; AMAT hits record highs; and CVNA slides.
Options bulls are targeting Intellia Therapeutics Inc (NASDAQ:NTLA) today, with 11,000 calls exchanged so far, nine times the amount typically seen at this point, in comparison to just 2,221 puts. The June 14 call is the most popular, followed by the August 14 call, with new positions opening at the latter. The biotech stock is up 10.3% to trade at $16.05, after the company earlier this week published strong phase 3 data for Lonvo-Z, its in vivo CRISPR gene editing candidate. The $16 level has provided pressure since a late-October bear gap, however.
Applied Materials Inc (NASDAQ:AMAT) stockis surging to record highs, last seen up 9.5% to trade at $622.27, earlier hitting a record $623.35. One of the many chip stocks rebounding after yesterday's selloff, AMAT also received a price-target hike from Citigroup to $710 from $550 after forecasts for global wafer fab equipment (WFE) spending were updated. Plus, Applied Materials also announced a new smart glasses display platform called SENZ. Year to date, the equity is up 140%.
One of the worst stocks on the New York Stock Exchange (NYSE) today, Carvana Co (NYSE:CVNA) was last seen down 7.8% at $64.44, in sympathy with CarMax (KMX) stock's post-earnings tumble. Margins concerns are weighing on the shares, while CNBC reported Tuesday that the company had "quietly" bought seven Stellantis locations since last year. Year to date, CVNA is down 23.8%.
HAE is a rare genetic disorder that causes recurrent and unpredictable swelling attacks.
The company on Saturday presented the data during a late-breaking session at the European Academy of Allergy & Clinical Immunology Annual Congress 2026, while the results were also published in the New England Journal of Medicine.
Lonvo-Z Meets Key Secondary Endpoints In HAELO StudyThe latest data build on previously announced results showing that the study met its primary endpoint.
During the efficacy evaluation period from weeks five through 28, patients treated with lonvo-z experienced an 87% reduction in mean monthly HAE attacks compared with those receiving placebo.
Researchers also reported that 62% of patients in the lonvo-z group remained both attack-free and therapy-free throughout the six-month evaluation period, compared with 11% of patients in the placebo arm. The difference met a key secondary endpoint with statistical significance.
Safety Profile Remains FavorableAccording to Intellia, lonvo-z demonstrated favorable safety and tolerability across the study.
All treatment-emergent adverse events observed during the primary observation period were classified as mild or moderate. The company reported no serious adverse events among patients receiving lonvo-z.
Analyst Compares To Recently Approved HAE TreatmentsLonvo-z, previously known as NTLA-2002, is designed as a one-time, in vivo CRISPR gene-editing therapy. The treatment aims to permanently reduce kallikrein levels by inactivating the KLKB1 gene following a single dose.
In an investor note on Monday, William Blair wrote, "Additional data on lonvo-z presented at EAACI further substantiated lonvo-z's competitiveness with Q4W donidalorsen on placebo-adjusted HAE attack rate reductions across multiple secondary endpoints."
Analyst Myles Minter further added, "We view these data as furthering
Intellia's case for regulatory approval following its expected completion of a rolling BLA for lonvo-z in the second half of 2026.
NTLA Stock Price Activity: Intellia Therapeutics shares were up 10.57% at $13.39 at the last check on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
June 13, 2026 07:30 ET | Source: Intellia Therapeutics, Inc.
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. The presentation and publication can be accessed from the Scientific Publications and Presentations section of intelliatx.com.
As previously announced, HAELO met its primary endpoint with an 87% reduction (p<0.0001) in mean monthly attacks in the lonvo-z arm vs. the placebo arm during the efficacy evaluation period (weeks 5 to 28). In addition, 62% of patients in the lonvo-z arm were entirely attack free and therapy free for the six-month efficacy evaluation period, compared with 11% of patients in the placebo arm (p<0.0001), a key secondary endpoint. Today, Intellia reported data for the trial’s other key secondary endpoints:
Key Secondary EndpointLonvo-z Arm (N=52)Placebo Arm (N=28)Monthly rate of attacks requiring on-demand treatment Weeks 5-28, mean (95% CI)
0.19 (0.10, 0.36)1.79 (1.27, 2.54)89% reduction (79%, 94%), p<0.0001Monthly rate of moderate/severe attacks Weeks 5-28, mean (95% CI)
0.11 (0.06, 0.23)1.23 (0.84, 1.81)91% reduction (81%, 96%), p<0.0001Change from baseline to Week 28 in AE-QoL total score, mean (95% CI)
-23.51 (-27.64, -19.38)-6.47 (-12.26, -0.68)-17.04 improvement (-24.15, -9.93), p<0.0001 AE-QoL: Angioedema Quality of Life score, which is a validated, angioedema-specific patient-reported outcome measure with a lower score indicating improved quality of life. A 6-point reduction is considered to be a clinically important improvement in AE-QoL.
CI: Confidence interval
Favorable safety and tolerability data were observed for lonvo-z. The most common treatment emergent adverse events (TEAEs) during the primary observation period (infusion through week 28) that were higher in the lonvo-z group compared to placebo were infusion-related reaction, headache, fatigue, back pain, and upper respiratory tract infection. All reported TEAEs were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.
“These are the first Phase 3 results to deliver on the much-heralded promise of in vivo CRISPR gene editing,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “Regardless of age or prior use of long-term prophylaxis therapies, it was observed that a single lonvo-z treatment significantly reduced HAE attacks for all patients during the efficacy evaluation period, with all patients remaining LTP free as of the data cutoff. We thank the many patients, physicians and caregivers who participated in HAELO and are excited to be advancing this highly differentiated candidate toward a potential approval.”
Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, and a HAELO principal investigator, added, “As a clinician who has witnessed patients struggle with the unpredictability and emotional toll of HAE, the prospect of offering lasting freedom from attacks and chronic medication with a one-time treatment is incredibly exciting. These results give me confidence that many patients will soon have the potential to enjoy a normal life.”
Today’s presentation and publication also included supplemental demographics, data and analyses, including:
A time plot showing that the mean monthly attack rate for patients receiving lonvo-z through the data cutoff (February 10, 2026) was well below the reported rate in prescreening while patients were receiving standard-of-care therapy;Patient-level data demonstrating that all patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks 5 to 28;An analysis showing that meaningful attack-rate reductions were observed for all evaluated subgroups;A breakdown showing that 20% of the patients who enrolled in HAELO reported having complete disease control (no attacks) as their best response to prior long-term prophylaxis therapies; andA plasma kallikrein time plot showing that protein levels decreased substantially by the first measurement (day 15), reached a steady state by week 5 and remained stable through the data cutoff. A rolling biologics license application (BLA) submission for lonvo-z was initiated in April with the U.S. Food and Drug Administration (FDA). The company continues to anticipate regulatory approval and a U.S. launch in the first half of 2027.
About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (formerly NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its plan to complete the submission of a biologics license application (“BLA”) for lonvo-z, its expectations regarding review and approval of that BLA, and its expectations regarding a potential U.S. launch of lonvo-z in the first half of 2027; and the potential of one dose of lonvo-z to become the first one-time treatment for HAE and to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials or regulatory filings due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
April 27, 2026 16:01 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.
Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares of common stock are being offered by Intellia pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-275740) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 24, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from: Jefferies LLC, by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Goldman Sachs & Co. LLC, by mail at Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding the proposed public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the proposed public offering; the safety, tolerability, efficacy, advancement and success of Intellia’s clinical programs; and Intellia’s ability to successfully execute its business and strategic plans, including the advancement, development and commercialization of its product candidates.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia’s other product candidates; and risks related to Intellia’s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
Key Takeaways Intellia shares fell 4% despite the phase III data meeting all endpoints for lonvo-z in HAE.NTLA's lonvo-z cut HAE attacks by 87% vs. placebo, with 62% of patients attack-free in the study.Intellia began its rolling BLA submission, targeting completion in H2 2026 and a launch in 2027. Shares of Intellia Therapeutics (NTLA - Free Report) declined 4% on Monday despite positive top-line data from the global phase III HAELO clinical trial evaluating lonvo-z for the treatment of patients with hereditary angioedema (HAE). Lonvo-z is a one-time, outpatient CRISPR-based therapy designed to inactivate the KLKB1 gene, thereby reducing kallikrein and bradykinin levels.
Key Highlights of NTLA’s Phase III HAELO StudyThe phase III randomized, placebo-controlled HAELO study evaluated the safety and efficacy of a one-time 50-milligram dose of lonvo-z in patients aged 16 years and older with type I or type II HAE. Data from the study demonstrated that a one-time infusion of lonvo-z reduced HAE attacks by 87% compared with placebo over the six-month evaluation period. Patients treated with lonvo-z had a much lower average monthly attack rate (0.26) versus 2.10 in the placebo group.
The study met its primary endpoint. It also met all key secondary endpoints with strong statistical significance, including a notably higher proportion of patients who were completely free from both attacks and ongoing therapy (62% versus 11% with placebo). The treatment was well-tolerated, with mild-to-moderate side effects.
Hereditary angioedema (HAE) is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin.
However, it seems that investors were not impressed by the data reported by the company and its stock declined.
Year to date, shares of NTLA have risen 45% against the industry’s 1.2% decline.
Image Source: Zacks Investment Research
NTLA Initiates Rolling Submission of BLA for lonvo-zIn a separate press release, Intellia announced that it has begun a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE.
The company expects to complete the BLA submission in the second half of 2026. If accepted, the FDA will determine whether the application qualifies for priority review and will set a target decision date. Intellia plans to commercially launch lonvo-z in the first half of 2027, as the world’s first in vivo CRISPR-based gene editing therapy, if approved.
NTLA’s Zacks Rank & Stocks to ConsiderIntellia Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and Indivior Pharmaceuticals (INDV - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) , which carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.59 to $2.87. Over the same period, EPS estimates for 2027 have surged from $3.01 to $3.25. CPRX shares have gained 25.5% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 90 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.94 to $3.00. Over the same period, EPS estimates for 2027 have surged from $3.22 to $3.29. INDV shares have lost 4.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.22 to $9.02. Over the same period, EPS estimates for 2027 have risen from $9.90 to $10.23. Year to date, shares of ANIP have gained 0.8%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
While the heyday of Cathie Wood’s investment management is, for the time being, firmly in the past, the popular ARK Innovation ETF (ARKK) has been having a respectable run in the last 12 months and unveiled its latest series of bets as recently as April 28.
ARKK ETF one-year price chart. Source: Google Specifically, ARKK revealed on Tuesday that it invested a total of nearly $42 million in four stocks: Alphabet (NASDAQ: GOOG), CoreWeave (NASDAQ: CRWV), Intellia Therapeutics (NASDAQ: NTLA), and Kratos Defense & Security Solutions (NASDAQ: KTOS).
The purchases of NTLA and KTOS shares ranged between $6 and $6.9 million, and together, the two account for just 0.13% of the exchange-traded fund (ETF).
Simultaneously, the market value of the April 28 Google stock investment is listed at $14.1 million – 0.14% of the ETF – and in CoreWeave at $14.8 million – 0.15%.
ARKK ETF April 28 investments. Source: Cathie’s Ark Cathie Wood invests $14.8 million in CoreWeave stock Elsewhere, the timing of the two bigger investments is interesting for a variety of reasons. CoreWeave is, as a company, seen as either a firm that is doomed to collapse or one of the most exciting investment opportunities of 2026.
Indeed, the former cryptocurrency miner made a pivot to becoming an artificial intelligence (AI) data center, securing backing from the semiconductor giant Nvidia (NASDAQ: NVDA).
Under the circumstances, Cathie Wood appears to be betting that the optimistic predictions regarding the advancements, proliferation, and adoption of AI made by many executives and Wall Street experts will prove correct, enabling CoreWeave to enjoy a veritable explosion of revenue and profits.
The risk associated with the investment, however, comes from a mix of factors, of which the fact that AI model usage remains subsidized, limiting eventual full adoption, and the many data center delays and cancellations are the most pointed.
Lastly, the buy appears to have been timed with the latest CRWV correction, considering the equity rallied 77% between March 30 and April 22, but then fell 13.88% to $105.53 on April 28.
Cathie Wood invests $14.1 million in Google stock Google, on the other hand, is a trade that came without a correction in the latest rally but appears to simultaneously be a bet that the blue-chip technology giant will offer impressive earnings after the closing bell on April 29, thus bolstering the upward momentum.
Google stock price YTD chart. Source: Finbold Looking long-term, Alphabet has been a relatively safe bet for decades due to its dominant market position, continued search engine leadership, and the foresight that enabled it to participate in multiple technology trends, including becoming one of the top companies in the ongoing AI boom.
Still, Google is somewhat exposed in the long term since it has made a significant bet that the current AI race will continue without major setbacks, while, according to numerous users, severely degrading the quality of its core search engine business over the last decade.
April 29, 2026 07:00 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock. The shares of common stock are being sold at a public offering price of $10.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $180 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Intellia. In addition, Intellia has granted the underwriters a 30-day option to purchase up to 2,511,628 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares of common stock are being offered by Intellia pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-275740) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 24, 2023 and automatically became effective upon filing. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on April 27, 2026. The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding Intellia’s anticipated public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the anticipated offering; the safety, tolerability, efficacy, advancement and success of Intellia’s clinical programs; and Intellia’s ability to successfully execute its business and strategic plans, including the advancement, development and commercialization of its product candidates.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia’s other product candidates; and risks related to Intellia’s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
Intellia Therapeutics (NASDAQ:NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an investigational in vivo CRISPR-based gene-editing therapy for hereditary angioedema (HAE), and provided an update on regulatory progress during a company conference call.
Company outlines lonvo-z strategy and HAE unmet need Chief Executive Officer John Leonard described the update as a milestone for “the entire CRISPR field” and people living with HAE, emphasizing Intellia’s focus on in vivo gene editing delivered to the liver. Leonard said Intellia was “the first in the world to dose patients with in vivo CRISPR-based candidates and the first to advance into phase III,” and characterized the newly reported results as the “world’s first phase III data for an in vivo gene-editing candidate.”
Chief Medical Officer David Lebwohl said HAE is driven by an imbalance in the kallikrein-kinin system that leads to unpredictable swelling attacks, including potentially fatal laryngeal events. Despite widespread use of long-term prophylaxis (LTP), Lebwohl said many patients still experience breakthrough attacks and face burdens from chronic treatment, including frequent administration and payer scrutiny. He estimated there are about 7,000 treated HAE patients in the U.S., with more than 60% on LTP, and said U.S. spending is “about $4 billion annually on chronic HAE medications alone,” excluding other healthcare costs.
Lebwohl said lonvo-z is designed to permanently inactivate the KLKB1 gene to reduce kallikrein and bradykinin and “reset the system.” He also described the intended administration as outpatient: patients took a steroid at home the day before dosing, then received additional premedication and a 2- to 4-hour IV infusion before going home.
Phase III HAELO design and enrollment Marc Riedl, Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at UC San Diego Health and a HAELO principal investigator, presented the Phase III results. Riedl said HAELO is a placebo-controlled, double-blind, randomized trial in Type 1 and Type 2 HAE, requiring LTP washout during screening to establish an LTP-free baseline attack rate during run-in. Patients were randomized 2:1 to a one-time 50 mg dose of lonvo-z or placebo.
Riedl said the six-month efficacy evaluation period ran from week 5 through week 28 post-dosing. After week 28, patients could enter a blinded crossover and were followed for 18 additional months before long-term follow-up.
A total of 80 patients enrolled, with 52 assigned to lonvo-z and 28 to placebo. Roughly 70% of patients in each arm were female, about half were enrolled in the U.S., and approximately 70% were using LTP at study entry, with lanadelumab most common. The mean monthly attack rate during run-in was 3.5 in both arms.
Efficacy: primary endpoint and attack-free outcomes Riedl said HAELO met the primary endpoint and all key secondary endpoints with statistical significance. For the primary endpoint (weeks 5–28), the placebo arm had a mean of 2.1 attacks per month versus 0.26 for lonvo-z, an 87% reduction.
Riedl also reported that 62% of lonvo-z patients were attack-free during the efficacy observation period versus 11% on placebo. He emphasized that these patients were also “therapy-free,” taking no other prophylactic or rescue medication during that period.
Within the lonvo-z arm, Riedl said 100% of patients achieved an attack-rate reduction from baseline. He reported 62% were attack-free and therapy-free, while the remaining 38% had not reached attack-free status over the full observation period but showed a 72% reduction versus baseline. Leonard later noted that this 38% bucket could include patients who experienced a single attack early in the observation window and none thereafter, and he said Intellia plans to present more detail at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in June, including swimmer plots and additional subgroup information.
Riedl said early post-crossover data suggested continued improvement, with mean monthly attack rates “near zero” by week 36 among patients who had reached that time point, though he cautioned patient numbers beyond week 28 were limited at the cutoff.
Safety, labeling considerations, and path to filing and launch Riedl said lonvo-z had a favorable safety and tolerability profile in HAELO as of the data cutoff, with all adverse events mild or moderate and no serious adverse events in the lonvo-z arm. The most common adverse events were infusion-related reactions that were mild to moderate and transient.
Leonard also addressed a question about liver tests, saying there was a single Grade 2 ALT elevation in the trial that occurred “a couple weeks out after dosing,” resolved spontaneously within a week, and was asymptomatic with no therapy provided.
On real-world expectations, Riedl said the 62% attack-free endpoint is challenging because trials rely heavily on patient-reported outcomes, which can capture variable symptoms such as abdominal pain that may be adjudicated as an HAE attack. He added that other HAE therapies often “outperformed in the real world” versus blinded trials, including in open-label extensions, as patient confidence in treatment grows over time.
Riedl said if approved, he would discuss lonvo-z with every patient, but emphasized patient preferences vary. He added that while some patients are satisfied with current therapies, “certainly half and probably more than half” of his patients still discuss ongoing attacks, symptoms, treatment burden, and interruptions due to coverage issues. He also said most patient questions about gene editing relate to long-term safety and that broader education will be important.
Riedl pushed back on the suggestion that on-demand therapies might be unnecessary, saying guidelines still recommend all patients maintain access to on-demand treatment given the risk of rare but life-threatening airway attacks, though he expects usage could decline over time.
Leonard said Intellia recently initiated a rolling biologics license application (BLA) with the FDA and is preparing for potential approval and launch, including building commercial leadership, engaging payers and advocacy groups, and identifying target treatment centers. He said the company plans to present additional data at EAACI and aims, “if approved,” to target a commercial launch in the first half of 2027.
Chief Financial Officer Edward Dulac said Intellia is considering collaboration and distribution agreements to reach patients outside the U.S. and has not disclosed timelines for non-U.S. filings. Dulac also said payer discussions have been ongoing and “very constructive,” noting payers often evaluate one-time therapies as a multiple of the average annual cost. He said the company expects lonvo-z to be priced at a premium, though no price has been set, and added that Intellia is mindful that aggressive pricing could increase resistance, including through step edits.
About Intellia Therapeutics (NASDAQ:NTLA) Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
Featured Articles Five stocks we like better than Intellia Therapeutics
May 01, 2026 16:01 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 208,850 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
May 05, 2026 07:30 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:
Bank of America Securities Health Care Conference
Date: Tuesday, May 12, 2026
Fireside Chat Time: 3:40 p.m. PT
Location: Las Vegas RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 20, 2026
Fireside Chat Time: 2:35 p.m. ET
Location: New York Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Chat Time: 4:55 p.m. ET
Location: New York The fireside chats will be webcast live. To join the webcasts, please visit the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com. Replays of the webcasts will be available on the same page for approximately 90 days following the events.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
Tuesday was a rough day for Shopify (SHOP +2.06%), Intellia Therapeutics (NTLA +1.23%), and GeneDX Holdings (WGS +12.28%) investors. All three growth stocks tumbled between 4% and 49%. As the market was selling off those once high-flying stocks, Cathie Wood was buying.
Wood's Ark Invest added to all three existing positions on Tuesday. They were the only three stocks Ark Invest bought during the trading day. Let's take a closer look at what could be drawing the founder and CEO of Ark Invest to buy into Shopify, Intellia Therapuetics, and GeneDX on the way down.
Image source: Getty Images.
1. Shopify Let's start with the good news. Shopify stock is nearly a 50-bagger since its IPO. It's even trading higher over the past year. However, the online marketplace operator is falling again after a poorly received financial update in which soft guidance ruined an otherwise solid performance.
Revenue rose 34% for the first quarter, fueled by a 35% jump in gross merchandise volume for the merchants leaning on Shopify's e-commerce solutions. Adjusted net income fared even better, surging 44%. Both ends of the income statement exceeded expectations, but a recurring theme this earnings season has been strong quarters tripped up by a cautionary near-term tone.
Today's Change
(
2.06
%) $
2.23
Current Price
$
110.43
Now for the bad news. Shopify expects year-over-year revenue growth to decelerate in the current quarter. It's targeting an increase in the high twenties on a percentage basis. This is pretty much where Wall Street pros were anyway, but it dulls the excitement over the first quarter's 34% top-line jump.
It also doesn't help that Shopify isn't exactly cheap. Even after Tuesday's 16% slide, the stock is still trading for more than 50 times forward earnings. Thankfully, a high P/E ratio hasn't stopped Shopify before. It's still generating gobs of free cash flow, and its guidance for the new quarter should extend its streak of a double-digit free cash flow margin to 12 consecutive quarters.
This high-beta stock will remain volatile. Wood doesn't have a problem with that. She's buying as others are selling, and betting against Shopify hasn't been a winning trade for investors with long-term horizons.
Today's Change
(
1.23
%) $
0.15
Current Price
$
12.35
2. Intellia Therapeutics Unlike the double-digit percentage hits for the other two stocks on Wood's shopping list on Tuesday, Intellia was limited to a 4% retreat. One of Wood's most popular gene-editing stocks, the developer of next-gen treatments based on CRISPR therapies is connecting with analysts.
Whitney Ijem at Canaccord boosted his firm's price target from $48 to $58 last week, encouraged by recent positive data from a phase 3 clinical trial of a promising treatment. He's not even the Street-high on the shares. One analyst thinks Intellia is headed to $95, a big deal for a stock trading in the low teens.
Today's Change
(
12.28
%) $
6.67
Current Price
$
60.99
3. GeneDX Holdings One of Tuesday's biggest losers was GeneDX. Shares of the genomics company specializing in the diagnosis of rare diseases shed nearly half of their value after posting disappointing first-quarter results. A report has to be pretty bad for a stock to plunge 49% in a single trading day, so let's take a closer look.
Revenue rose 17% to $102.3 million through the first three months of this year. After seeing revenue soar 51% and then 40% in the past two years, analysts were holding out for a nearly 30% increase on the top line for the quarter. GeneDX's bread-and-butter exome and genome revenue rose a respectable 27%, but shortfalls elsewhere -- including its average reimbursement rates -- dragged overall results down. It also fell short of expectations on the bottom line.
This wasn't just a one-time fluke. GeneDX is resetting expectations. It now sees $475 million to $490 million in revenue for all of 2026, down from the $540 million to $555 million it was targeting earlier this year. After coming up short by $10 million on the top line in the first quarter, it's slashing the midpoint of its full-year outlook by $65 million. This appears to be a situation that will get worse instead of better in the near term.
Intellia Therapeutics, Inc. (NTLA - Free Report) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of +16.4%.
Revenues are expected to be $15.53 million, down 6.6% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 5.31% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Intellia Therapeutics?For Intellia Therapeutics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +6.14%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Intellia Therapeutics will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Intellia Therapeutics would post a loss of$0.99 per share when it actually produced a loss of -$0.83, delivering a surprise of +16.16%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Intellia Therapeutics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U. S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass.
Intellia Therapeutics, Inc. (NTLA - Free Report) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +11.60%. A quarter ago, it was expected that this company would post a loss of $0.99 per share when it actually produced a loss of $0.83, delivering a surprise of +16.16%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Intellia Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $15.05 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 3.12%. This compares to year-ago revenues of $16.63 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Intellia Therapeutics shares have added about 56.7% since the beginning of the year versus the S&P 500's gain of 8.1%.
What's Next for Intellia Therapeutics?While Intellia Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Intellia Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.86 on $15.13 million in revenues for the coming quarter and -$3.50 on $68.64 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Gossamer Bio (GOSS - Free Report) , is yet to report results for the quarter ended March 2026.
This biopharmaceutical company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of -12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Gossamer Bio's revenues are expected to be $5.57 million, down 43.7% from the year-ago quarter.
Key Takeaways NTLA posted a narrower Q1 loss as research and development costs fell, though revenues declined 9.5% y/y.NTLA resumed phase III nex-z studies after the FDA lifted clinical holds in ATTR-CM and ATTRv-PN.Intellia began a rolling FDA filing for lonvo-z after phase III data showed 87% fewer HAE attacks. Intellia Therapeutics (NTLA - Free Report) incurred first-quarter 2026 loss of 81 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, the company had incurred a loss of $1.10 per share.
Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $15 million for the first quarter of 2026, which missed the Zacks Consensus Estimate of $16 million. Total revenues declined 9.5% year over year.
Year to date, shares of NTLA have surged 60.4% against the industry’s 2.7% decline.
Image Source: Zacks Investment Research
NTLA’s Q1 Results in DetailResearch and development expenses totaled $80.7 million, down 25.5% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and reduced spending on research materials and contracted services.
General and administrative expenses in the first quarter were $34.8 million, up 20.1% year over year, primarily due to continued investments in building the company’s commercial infrastructure and higher legal expenses, partially offset by lower stock-based compensation.
As of March 31, 2026, Intellia had cash, cash equivalents and marketable securities worth $517.2 million compared with $605.1 million as of Dec. 31, 2025.
Following an underwritten public offering of common stock, the company expects its cash runway to support operations into 2028.
NTLA's Recent Pipeline UpdatesIntellia has collaborated with Regeneron Pharmaceuticals (REGN - Free Report) to develop its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
In March, the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III MAGNITUDE study evaluating nex-z in patients with ATTR-CM.
Earlier this year, the FDA lifted the clinical hold on the IND application for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in this study is expected to be completed in the second half of 2026.
With the removal of the clinical hold, Intellia is now focusing on completing patient enrollment in both late-stage studies as promptly as possible.
In April, Intellia announced top-line data from the global phase III HAELO study evaluating lonvo-z, an in vivo CRISPR gene editing therapy, for the treatment of hereditary angioedema (HAE). The study met its primary endpoint and all key secondary endpoints.
The study demonstrated that a one-time infusion of lonvo-z reduced HAE attacks by 87% compared with placebo over the six-month evaluation period. Patients treated with lonvo-z had a much lower average monthly attack rate (0.26) versus 2.10 in the placebo group. Per data, the company initiated a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE.
The company expects to complete the BLA submission in the second half of 2026. Intellia plans to commercially launch lonvo-z in the first half of 2027, as the world’s first in vivo CRISPR-based gene editing therapy, if approved.
NTLA’s Zacks Rank & Stocks to ConsiderIntellia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amarin Corporation (AMRN - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , both currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 7.6% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 8.2% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Key Takeaways Intellia advanced phase III studies for nex-z in ATTR amyloidosis after the FDA lifted clinical holds.NTLA said the phase III HAELO study for lonvo-z met primary and key secondary endpoints.Intellia plans a 2027 launch for lonvo-z, pending FDA approval after completing BLA submission. Intellia Therapeutics (NTLA - Free Report) has been making decent progress with the advancement of its two pipeline candidates, nex-z (or, NTLA-2001) for transthyretin (ATTR) amyloidosis and lonvo-z (or NTLA-2002) for hereditary angioedema (HAE).
Intellia is developing nex-z in collaboration with Regeneron Pharmaceuticals (REGN - Free Report) . The candidate is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively.
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The company’s top line currently comprises only collaboration revenues from its partners, like Regeneron and others.
In March, the FDA lifted the clinical hold on the investigational new drug (IND) application for the phase III MAGNITUDE study evaluating nex-z in patients with ATTR-CM.
Earlier this year, the FDA lifted the clinical hold on the IND application for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in this study is expected to be completed in the second half of 2026.
Intellia is now focusing on completing patient enrollment in both late-stage studies as promptly as possible. The successful development of nex-z could provide impetus to the stock and create long-term growth visibility.
Meanwhile, last month, Intellia announced that the phase III HAELO study evaluating lonvo-z, an in vivo CRISPR gene editing therapy, for the treatment of HAE, has met its primary endpoint and all key secondary endpoints.
Simultaneously, NTLA initiated a rolling submission of a biologics license application (BLA) to the FDA seeking approval for lonvo-z for the treatment of HAE. The company expects to complete the BLA submission in the second half of 2026. Intellia plans to commercially launch lonvo-z in the first half of 2027, upon potential approval.
The successful development of its pipeline candidates will be a huge boost to Intellia. However, any regulatory or developmental setback related to ongoing studies will be a major setback. Growing competition in the target market also remains a worry.
NTLA's Competition in the Target MarketWhile Intellia’s pipeline of innovative CRISPR-based therapies appears promising, developing these candidates remains a complex and challenging process. Even if successfully developed and approved, the therapies are likely to face competition from other companies leveraging CRISPR/Cas9 gene-editing technology to target diseases across similar therapeutic areas.
CRISPR Therapeutics (CRSP - Free Report) is the first and only company in the world to market a CRISPR/Cas9-based therapy. CRSP’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease and transfusion-dependent beta-thalassemia.
CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization.
Beam Therapeutics (BEAM - Free Report) is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with SCD. BEAM plans to submit a BLA for risto-cel by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively.
NTLA's Price Performance, Valuation and EstimatesYear to date, shares of Intellia have rallied 41.1% against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 2.46, lower than 3.13 for the industry. The stock is trading below its five-year mean of 2.58.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intellia’s 2026 loss per share has narrowed from $3.53 to $3.35 over the past 30 days. Loss per share estimates for 2027 have widened from $1.22 to $1.54 during the same time frame.
Image Source: Zacks Investment Research
NTLA's Zacks RankIntellia currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways Intellia reported positive phase III data for lonvo-z and targets a 2027 U.S. launch. NTLA resumed nex-z phase III studies after the FDA lifted prior clinical holds in 2026. ADMA faced weaker Bivigam sales as pricing pressure and elevated IG inventories weighed on demand. ADMA Biologics (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Intellia Therapeutics (NTLA - Free Report) is a biopharmaceutical company focused on advancing CRISPR gene-editing and related technologies to develop potentially curative therapies for severe diseases. Leveraging deep expertise in science, technology, and clinical development, the company aims to transform patient care by targeting the underlying causes of disease and redefining the future of medicine.
ADMA Biologics and Intellia Therapeutics operate in distinct areas of biotechnology, but they are comparable in terms of market capitalization, as both are generally viewed as small- to mid-cap biotech companies.
Hence, let us delve into their fundamentals, growth prospects, challenges and valuation levels to make a prudent choice.
The Case for ADMA Biologics ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
However, ADMA is currently grappling with macro challenges in the immunoglobulin (IG) products market.
Total revenues in the first quarter were $114.5 million, down 0.3% from the year-ago quarter’s level. Bivigam revenues declined 54% year over year.
Management noted that increased competition, elevated channel inventories and aggressive pricing activity in standard IG products created temporary pressure on top-line performance, particularly for Bivigam.
Late-quarter inventory shifts pushed certain contractual purchase orders expected in March into early April, affecting the timing of reported revenues. The company said these delays were partly due to temporary shortages in required safety stock levels at some customers and were resolved within the applicable cure period.
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. It remained the key contributor to ADMA’s revenue performance, while the company’s other product lines trended in the opposite direction.
Asceniv recorded 28% year-over-year revenue growth, driven by record utilization, expanding prescriber adoption, strong patient adherence and continued new patient starts.
ADMA emphasized that underlying Asceniv demand remained strong, citing record utilization growth, record new patient starts, expanding prescriber breadth and steady patient adherence. ADMA also noted that April demand supported a second-quarter run rate consistent with first-quarter direct sales, giving early signs of normalization in ordering patterns.
ADMA continued progressing SG-001, its hyperimmune globulin program targeting S. pneumoniae. Management reiterated a capital-efficient approach to development and believes the program could represent a meaningful long-term opportunity, citing an estimated $300 million to $500 million annual market opportunity if approved.
The Case for NTLA Intellia Therapeutics represents a high-growth biotechnology company with significant upside potential driven by its leadership in CRISPR-based gene-editing therapies. The company has spent more than a decade developing proprietary technologies, including gene editing, oligonucleotides and lipid nanoparticle delivery systems, to advance first-in-class treatments for severe diseases.
Its lead candidates, lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) and nexiguran ziclumeran for ATTR amyloidosis, are the first in vivo genome-editing therapies to enter phase III development. These one-time intravenous treatments target diseases with high unmet need and could potentially offer durable or curative benefits, creating a large commercial opportunity if approved.
Lonvoguran ziclumeran is an investigational one-time CRISPR-based therapy developed by NTLA to treat HAE by permanently reducing kallikrein production in the liver, with the goal of dramatically lowering or eliminating HAE attacks.
In the phase III HAELO study, lonvo-z achieved positive top-line results, reducing HAE attacks by 87% versus placebo and meeting all key secondary endpoints with strong statistical significance. The therapy also demonstrated favorable safety and tolerability, with no serious adverse events reported. Following these results, NTLA initiated a rolling BLA submission to the FDA, targeting a potential launch in the first half of 2027 in the United States.
NTLA’s other candidate, nexiguran ziclumeran (nex-z) is an investigational one-time CRISPR-based therapy designed to silence the TTR gene in the liver, potentially halting or reversing ATTR amyloidosis through durable reduction of TTR protein levels.
The company faced a temporary setback in late 2025 after a patient death led the FDA to place clinical holds on the phase III MAGNITUDE studies on nex-z. However, the FDA lifted both holds in early 2026, allowing patient screening to resume. Nex-z is being co-developed with Regeneron Pharmaceuticals, which shares development costs and future commercial profits under the collaboration agreement.
The successful development and commercialization of these candidates could position Intellia as a pioneer in the emerging gene-editing market and significantly expand its long-term revenue potential. Intellia ended the first quarter of 2026 with $517.2 million in cash, cash equivalents, and marketable securities.
The company further strengthened its balance sheet through a public stock offering in April 2026 that generated approximately $207 million in gross proceeds. Management expects its current cash reserves to fund operations into 2028, extending well beyond the anticipated U.S. commercial launch of lonvo-z in the first half of 2027.
A Look at Estimates: ADMA vs NTLA The Zacks Consensus Estimate for ADMA’s 2026 sales implies a year-over-year increase of 5.86%, and that for earnings per share (EPS) suggests an improvement of 40%. However, EPS estimates for 2026 and 2027 have moved south in the past 60 days.
ADMA’s Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for NTLA’s 2026 sales implies a year-over-year decrease of 7.75%, while that for EPS suggests an improvement of 13.65%. Loss estimates for both 2026 and 2027 have narrowed in the past 60 days.
NTLA Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of ADMA and NTLAFrom a price-performance perspective, NTLA has performed well so far this year versus ADMA. Shares of ADMA have plunged 55.3%. In contrast, NTLA shares have surged 40.3%. The industry has declined 0.5% in the said period.
Image Source: Zacks Investment Research
From a valuation standpoint, ADMA’s shares currently trade at 3.19X forward sales, lower than 9.71X for NTLA.
Image Source: Zacks Investment Research
Which Stock Is a Better Pick for Now? ADMA currently has a Zacks Rank #5 (Strong Sell) while NTLA carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Although demand for ADMA’s Asceniv continues to be solid, broader pressure across the U.S. plasma-derived products space suggests a more cautious near-term outlook. Competitive intensity, pricing dynamics and market share concerns could continue to weigh on growth visibility and margin expansion prospects.
In contrast, Intellia is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies designed to potentially cure severe diseases by targeting their underlying genetic causes. NTLA strengthened its investment case after reporting positive phase III top-line data for lonvo-z in April 2026, with a commercial launch planned for the first half of 2027. Successful commercialization could position Intellia as a pioneer in the emerging gene-editing market and significantly expand its long-term revenue potential.
Hence, we prefer NTLA over ADMA, given its significant growth opportunity in genetic medicine and the recent positive revisions to earnings estimates.
Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack reduction, but market reaction was muted due to safety concerns and the competitive landscape. The FDA lifted clinical holds on Nex-Z Phase 3 trials, enabling advancement in a $16.8bn ATTR market with a differentiated one-time treatment profile.
June 01, 2026 07:30 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.
Late-Breaking Oral Presentation Details:
Title: HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema
Session: Immune deficiencies and autoimmunity
Data and Time: Saturday, June 13, 2026, from 8:45 – 9:45 a.m. TRT
Presentation Number: 100217
Presenter: Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam Poster Presentation Details:
Title: Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe
Session: Immune deficiencies and autoimmunity 02
Data and Time: Friday, June 12, 2026, from 12:00 – 1:00 p.m. TRT
Poster Number: D1.336
Presenter: Henriette Farkas, M.D., Ph.D., Professor of Allergy and Clinical Immunology Director of the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
June 05, 2026 16:05 ET | Source: Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 47,150 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
A month has gone by since the last earnings report for Intellia Therapeutics, Inc. (NTLA - Free Report) . Shares have lost about 7.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Intellia Therapeutics due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Intellia Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.
Intellia Q1 Earnings Beat Estimates, Revenues Miss MarkIntellia incurred a first-quarter 2026 loss of 81 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, the company had incurred a loss of $1.10 per share.
Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $15 million for the first quarter of 2026, which missed the Zacks Consensus Estimate of $16 million. Total revenues declined 9.5% year over year.
Quarter in DetailResearch and development expenses totaled $80.7 million, down 25.5% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and reduced spending on research materials and contracted services.
General and administrative expenses in the first quarter were $34.8 million, up 20.1% year over year, primarily due to continued investments in building the company’s commercial infrastructure and higher legal expenses, partially offset by lower stock-based compensation.
As of March 31, 2026, Intellia had cash, cash equivalents and marketable securities worth $517.2 million compared with $605.1 million as of Dec. 31, 2025.
Following an underwritten public offering of common stock, the company expects its cash runway to support operations into 2028.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.
The consensus estimate has shifted 7.62% due to these changes.
VGM ScoresAt this time, Intellia Therapeutics has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the fifth quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Intellia Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerIntellia Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , has gained 4.1% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Incyte reported revenues of $1.27 billion in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $1.81 for the same period compares with $1.16 a year ago.
Incyte is expected to post earnings of $1.80 per share for the current quarter, representing a year-over-year change of +14.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -3.3%.
Incyte has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
